Passage Bio, Inc. is evaluating PBFT02 for the treatment of Fatal Thought Disorder (FTD), noting that the drug elevates PGRN in cerebrospinal fluid (CSF) and reduces the rate of NfL increase.
1 report, 0 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Passage Bio, Inc. is evaluating PBFT02 for the treatment of Fatal Thought Disorder (FTD), noting that the drug elevates PGRN in cerebrospinal fluid (CSF) and reduces the rate of NfL increase.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
ICM
Swiss OEM maker of blank Compact Cassettes and audio Compact Discs
Coverage
Newest first; wire copies grouped- Unknown outlet